A German hospital study found that nearly 9 in 10 inpatients diagnosed with cannabis use disorder were taking at least one medication flagged by screening tools as potentially interacting with cannabis, with opioid substitution drugs like levomethadone posing the greatest theoretical concern. Importantly, no actual patient harms were measured, so these flags represent potential risks rather than confirmed clinical events.

Cannabis legalization continues to expand globally, and patients admitted to addiction medicine wards frequently take complex medication regimens alongside ongoing or recent cannabis use. Despite this reality, no prior study had systematically quantified how often the medications prescribed to hospitalized cannabis use disorder patients carry potential interaction flags with cannabis itself. Understanding this landscape is a necessary first step before clinicians can develop evidence-based monitoring protocols, and this study provides the first prevalence estimate for that interaction burden in an inpatient setting.

Cannabis use disorder represents a growing clinical challenge as legalization accelerates, and the pharmacological complexity of patients admitted to addiction wards creates a rich environment for drug interactions. THC and CBD are metabolized through cytochrome P450 pathways, particularly CYP3A4 and CYP2C9, and can inhibit or induce enzymes involved in the metabolism of many commonly prescribed psychotropic and analgesic medications. This study, conducted at a 12-bed specialized addiction ward at Hannover Medical School in Germany, retrospectively reviewed the medication charts of 301 admissions involving 179 individual patients diagnosed with ICD-10 cannabis use disorder over a six-year period from 2016 to 2021. Researchers used two commercial interaction-screening databases, drugs.com and UpToDate Lexicomp, to identify and classify potential cannabis-drug interactions and drug-drug interactions among co-prescribed medications.

The headline finding was that 89.4% of all cases (269 of 301) involved at least one medication flagged for a potential interaction with cannabis. A total of 543 potential cannabis-drug interactions were identified, including 27 classified as major and 366 as moderate. Levomethadone, buprenorphine, and morphine dominated the serious interaction category, with nervous system drugs accounting for 94.4% of the most severe flags. An additional 196 drug-drug interactions were identified among co-prescribed medications, with 25.5% rated “avoid combination” and most involving levomethadone paired with other psychotropic agents. Critically, this study measured no actual adverse drug reactions, patient outcomes, or pharmacokinetic parameters. All interactions represent database-flagged potential risks, and the authors acknowledge that prospective clinical studies measuring real-world harms are needed to determine whether these theoretical risks translate into patient-level consequences.

This study does something valuable: it shines a light on a blind spot. We know that cannabis interacts with cytochrome P450 enzymes, and we know that patients on addiction wards are often taking complex medication regimens, yet no one had previously quantified how frequently those two facts collide. The 89% prevalence figure is striking and appropriately attention-grabbing. Where caution is required, however, is in the gap between “flagged by a screening tool” and “actually caused harm.” Commercial interaction databases are designed to be sensitive, not specific, and many of the flags identified here may carry minimal real-world clinical significance.

In my own practice, I already treat opioid substitution therapy combined with cannabis as a high-vigilance scenario. I counsel patients on the additive CNS depression risk, monitor for sedation and respiratory changes, and ensure that any prescriber adjustments are communicated across the care team. What this study reinforces for me is the importance of running structured interaction checks at admission for every patient who uses cannabis, especially those on methadone or levomethadone. It does not, however, change my prescribing thresholds, because we still lack the outcome data to know which of these flagged interactions genuinely matter at the bedside.

This study occupies an early position in the research arc for cannabis-drug interaction pharmacovigilance. It establishes baseline prevalence in a defined clinical population, which is a necessary precursor to the prospective outcome studies and pharmacokinetic validation work that would be needed before interaction risk can be meaningfully quantified. Clinicians should view these findings as hypothesis-generating rather than practice-changing. The high interaction prevalence is not surprising given that commercial screening tools are calibrated for sensitivity, and the predominantly psychiatric and substance-use medication profile of this cohort naturally overlaps heavily with the CNS-active drug classes most likely to share metabolic pathways with cannabinoids.

From a pharmacological standpoint, the dominance of opioid substitution agents in the serious interaction category is biologically plausible. Both THC and methadone (or levomethadone) are CYP3A4 substrates, and additive CNS depression is a recognized concern with any opioid-cannabinoid combination. Clinicians managing patients on opioid substitution therapy who also use cannabis should be attentive to sedation, respiratory rate, and QTc prolongation, particularly when levomethadone is involved. One

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care